NCT02183350View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

August 31, 2005

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

BI 1356 BS - single rising dose

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02183350 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter